explore -WSS

explore

author：knowledge 2025-09-27 23:52:59 - browse：5

Electrocardiogram in the shape of the United States map — Adobe

The market for artificial intelligence in health care is about as transparent as a brick wall. New tools achieve impressive results in published studies. But it is often difficult to compare them head to head with similar products, or tell whether they will work on different kinds of patients.

A new company is promising to change that — if it can convince AI developers to expose their products to more rigorous testing.

Called Dandelion Health, the New York-based firm is launching a first-of-its-kind public service to evaluate AI products on independent data designed to root out weaknesses and reveal bias. The company said Wednesday its initial pilot program, to begin next month, will focus on testing algorithms that use electrocardiograms to predict heart conditions.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： White House Covid adviser calls on docs to combat misinformation

Wikipedia

WSS

What happened to the House vote on health price transparency?

After gene therapy, two congenitally deaf children hear for the first time

Shionogi licenses Pompe disease therapy from Maze Therapeutics

How the messy conversation about Dolly changed bioethics

Eli Lilly CEO gives to Mike Pence presidential super PAC

Eli Lilly CEO gives to Mike Pence presidential super PAC

entertainment

explore

explore

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Midwives could help bridge maternal health disparities in the U.S.

Hollywood unions extend contract negotiations for actors

Study: AI not yet building 'n

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Transgender sports debate: Physicians say bans are health issue

At least 13 dead in Texas as scorching temps continue

FDA weighs limits of animal data in assessing artificial wombs

United colonoscopy coverage change 'may cost lives,' doctors say

PBMs drew scrutiny in House hearing — and so did pharma

hotspot

After gene therapy, two congenitally deaf children hear for the first time

Why the drug industry's warnings on the IRA's impact fall short

FDA panel to weigh safety of artificial wombs for preterm births

FDA panel to weigh safety of artificial wombs for preterm births

Grad students accuse University of California of wage theft

Bird flu outbreak in cows is latest avian flu curveball

explore

Wikipedia

entertainment

focus